8-K: Allurion Technologies Faces NYSE Delisting Threat After Share Price Falls Below $1

Allurion Technologies has received a notice from the NYSE for non-compliance with listing standards due to its stock price falling below $1.00, triggering a potential delisting.

Summary

• Allurion Technologies received a notice from the New York Stock Exchange (NYSE) because its average stock price fell below $1.00 over a 30-day period ending August 8, 2024.
• The company has a six-month cure period to regain compliance by achieving a closing share price of at least $1.00 and an average closing share price of at least $1.00 over a 30-day period ending on the last trading day of any calendar month during the cure period.
• Allurion is considering options to regain compliance, including a potential reverse stock split, which would require shareholder approval.
• The notice does not immediately delist the stock, and it will continue to trade on the NYSE under the symbol ALUR with a '.BC' designation.
• Failure to regain compliance could lead to suspension and delisting from the NYSE, which could negatively impact the company's stock liquidity and market price.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The potential for a reverse stock split also indicates a weak stock performance.

Positives

• The notice does not result in immediate delisting, and the company has a six-month cure period to regain compliance.
• Allurion intends to remain listed on the NYSE and is exploring options to regain compliance.
• The notice is not expected to impact the company's ongoing business operations or reporting requirements with the SEC.

Negatives

• The company's stock price has fallen below the NYSE's minimum listing requirement of $1.00.
• There is a risk of delisting if the company fails to regain compliance within the cure period.
• Delisting could negatively impact the company's stock liquidity and market price.

Risks

• The company may not be able to regain compliance with the NYSE listing standards within the six-month cure period.
• A reverse stock split, if implemented, may not be sufficient to raise the stock price above $1.00.
• Delisting from the NYSE could negatively impact the company's ability to raise capital and its overall market perception.
• The notice and potential delisting could impact the company's results of operations, business operations, and reputation.

Future Outlook

The company intends to remain listed on the NYSE and is considering options, including a reverse stock split, to regain compliance with listing standards. However, there is no guarantee that these actions will be successful.

Management Comments

• The company plans to notify the NYSE that it intends to cure the stock price deficiency and return to compliance.
• Allurion is considering all available options to regain compliance with the NYSE's continued listing standards, including, but not limited to, a reverse stock split, subject to stockholder approval.

Industry Context

This announcement highlights the challenges faced by companies with declining stock prices, particularly in the current economic climate. It is not uncommon for companies to receive delisting notices, and the response often involves measures like reverse stock splits to regain compliance.

Comparison to Industry Standards

• Many companies in the biotech and medical device sectors face similar challenges with stock price volatility, especially during development and commercialization phases.
• A reverse stock split is a common strategy used by companies to increase their stock price and avoid delisting, but it does not guarantee long-term success.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting risks and have taken measures to regain compliance.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and partners may have concerns about the company's long-term viability.

Next Steps

• Allurion will notify the NYSE of its intent to cure the stock price deficiency.
• The company will explore options to regain compliance, including a potential reverse stock split.
• Shareholder approval will be required for a reverse stock split.
• The company will need to achieve a closing share price of at least $1.00 and an average closing share price of at least $1.00 over a 30-day period to regain compliance.

Key Dates

Keywords

NYSE, delisting, stock price, compliance, reverse stock split, listing standards, Allurion Technologies, ALUR